866-997-4948(US-Canada Toll Free)

Urocidin (Bladder Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Bladder Cancer

No. of Pages : 24 Pages

 

GlobalDatas pharmaceuticals report, Urocidin (Bladder Cancer) Analysis and Forecasts to 2020 provides Urocidin global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Urocidin including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Urocidin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2012-2020 for Urocidin

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Bladder Cancer Market 4
2.2 Bladder Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 7

3 Baldder Cancer Disease: Market Characterization 8
3.1 Bladder Cancer Disease Market 8
3.2 Bladder Cancer Disease Market Forecasts and CAGR 8
3.3 Drivers for the Bladder Cancer Disease Market 8
3.3.1 High Prevalence 9
3.3.2 High Incidence 9
3.3.3 High Survival Rate 10
3.3.4 High lifetime costs 10

4 TNM Classification of bladder cancer 11
4.1 American Urological Association 11

5 Urocidin 14
5.1 Introduction 14
5.2 Mechanism of Action 14
5.3 Clinical Studies 14
5.4 Approval History of Urocidin 16
5.5 Fast Track Designation 17
5.6 Patent portfolio of its Mycobacterial Cell Wall-DNA Complex (MCC) 17
5.7 Milestone payment from Endo Pharmaceuticals 18
5.8 Sales drivers 18
5.8.1 Bladder Cancer Market 18
5.8.2 BCG Toxicity Profile 18
5.8.3 Large Unmet need 18
5.8.4 BCG has limited use in second line therapy 18
5.9 Drug Risk Benefit Score 19
5.9.1 Efficacy 19
5.9.2 Safety 19
5.9.3 Compliance 19
5.9.4 Dosing Convenience 19
5.10 Sales forecast 20
5.10.1 Target patient Pool of Urocidin 20
5.10.2 Dosing 20
5.10.3 Market Penetration 20
5.10.4 Annual Cost of Therapy 21
5.10.5 Sales Projections of Urocidin 21

6 Bladder Cancer Market: Appendix 22
6.1 Market Definitions 22
6.2 List of Abberiviations 22
6.3 Research Methodology 22
6.3.1 Coverage 22
6.3.2 Secondary Research 22
6.3.3 Forecasting 23
6.3.4 Number of Patients Approved to take the Drug 23
6.3.5 Net Penetration of Drug 23
6.3.6 Net Annual Dosing 23
6.3.7 Annual Cost of Therapy 24
6.3.8 Primary Research 24
6.3.9 Expert Panels 24
6.4 Contact Us 24
6.5 Disclaimer 24
6.6 Sources 24

 

List of Table


Table 1: Baldder Cancer Incidences & Mortality 5
Table 2: Bladder Cancer, Global, Market Forecast ($bn), 20022020 8
Table 3: Drug Risk Benefit Score of Urocidin 19

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage share of risk factors in Developed Countries 6
Figure 4: Percentage share of risk factors in Developing Countries 6
Figure 5: Smoking Consumption Curve, US 6
Figure 6: Forecasted Global Bladder Cancer Market 8
Figure 7: All Cancer Incidence Worldwide 9
Figure 8: Bladder Cancer Incidence Worldwide 9
Figure 9: Broad Classification of Bladder Cancer 11
Figure 10: Classification of NMI Bladder Cancer 11
Figure 11: Detailed TNM Classifications 12
Figure 12: Classification of NMI Bladder Cancer 13
Figure 13: Bioniche Expectation of Phase-III Results 14
Figure 14: Phase II Results, Urocidin 15
Figure 15: Approval History of Urocidin 16
Figure 16: Drug Model Diagram of Urocidin 20
Figure 17: Global Forecasted Sales of Urocidin & Sales Distribution 21
Figure 18: Distribution of Urocidin Sales in Major Countries 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *